Anti-hormonal maintenance treatment with/without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in HR+/HER2- metastatic breast cancer: a phase II trial (AMICA) GBG 97

Authors :: Jana Barinoff
V Müller
K Lübbe
M Thill
V. Tierbach
Christoph Mundhenke
Martina Schmidt
G Minckwitz
S Seiler
Jenny Furlanetto
S Loibl
Thomas Decker
Carsten Denkert
Fenja Seither
Source :: Senologie - Zeitschrift für Mammadiagnostik und -therapie.
Publication Year :: 2018
Publisher :: Georg Thieme Verlag KG, 2018.

Subjects :: Oncology
Chemotherapy
medicine.medical_specialty
business.industry
medicine.medical_treatment
Internal medicine
medicine
Ribociclib
Line (text file)
medicine.disease
business
Metastatic breast cancer
Hormone

Full Text Access

Tools